Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
- 16.04.2024
- Retinal Disorders
Erschienen in:
- Verfasst von
- Mio Morizane Hosokawa
- Chihiro Ouchi
- Yusuke Shiode
- Shuhei Kimura
- Ryo Matoba
- Tetsuro Morita
- Yuki Morizane
Abstract
Purpose
To investigate the influence of submacular hemorrhage (SMH) at baseline on long-term visual outcomes of patients with typical age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV) treated with intravitreal aflibercept (IVA).
Methods
In this retrospective study, eyes of treatment-naïve patients with tAMD and PCV who initiated IVA under a treat-and-extend regimen and were followed up for ≥ 5 years were classified into the tAMD-SMH ( +), tAMD-SMH (-), PCV-SMH ( +), and PCV-SMH (-) groups based on the presence of SMH at baseline. Best-corrected visual acuity (BCVA) changes and macular fibrosis and atrophy incidences were assessed.
Results
This study included 127 eyes (127 patients), including 51 with tAMD and 76 with PCV; 18 eyes had SMH at baseline. In the tAMD-SMH ( +) group (n = 6), the mean logMAR BCVA significantly deteriorated from 0.59 ± 0.45 at baseline to 0.88 ± 0.47 at the final visit (P = 0.024). No significant BCVA changes were observed in the tAMD-SMH (-) (n = 45), PCV-SMH ( +) (n = 12), or PCV-SMH (-) (n = 64) groups (all P > 0.05). The tAMD-SMH ( +) group showed a significantly higher incidence of macular fibrosis at the final visit than did the tAMD-SMH (-) group (P = 0.042). There was no influence of baseline SMH on the macular fibrosis incidence in eyes with PCV and the macular atrophy incidence in eyes with tAMD and PCV.
Conclusion
The presence of SMH at baseline resulted in poorer long-term visual acuity in eyes with tAMD, even with aflibercept treatment. However, no such influence was observed in eyes with PCV.
Anzeige
- Titel
- Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
- Verfasst von
-
Mio Morizane Hosokawa
Chihiro Ouchi
Yusuke Shiode
Shuhei Kimura
Ryo Matoba
Tetsuro Morita
Yuki Morizane
- Publikationsdatum
- 16.04.2024
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2024
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X - DOI
- https://doi.org/10.1007/s00417-024-06453-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
